)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Entrada Therapeutics
Entrada Therapeutics (TRDA) investor relations material
Entrada Therapeutics Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026
Program pipeline and clinical focus
Lead programs target Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1, using proprietary endosomal escape vehicles (EEVs) for intracellular delivery.
Recent expansion into ocular diseases, with initial focus on Usher syndrome type 1A.
Multiple clinical data inflection points expected in 2024, including Q2 and mid-year updates for DMD programs and a year-end 12 mg/kg dose readout.
Vertex-partnered DM1 program (VX-670) to complete dosing and enrollment by mid-year.
EEV platform enables parallel development across exons 44, 45, 50, and 51, de-risking future programs.
Clinical data strategy and regulatory engagement
Q2 data for ENTR-601-44 (6 mg/kg) expected to show double-digit dystrophin levels and robust safety, with a higher 12 mg/kg cohort readout by year-end.
Functional benefit is being measured but not expected in the first cohort due to short follow-up; longer-term open-label extension will assess this.
U.S. adult study enrollment planned for the second half of 2024, pending review of Q2 data and further FDA discussions on dose escalation.
FDA's initial dose cap was based on limited data; new clinical results may support higher dosing and harmonization with ex-U.S. protocols.
Positive Q2 data would de-risk and accelerate development for additional exons and support regulatory confidence.
Competitive landscape and differentiation
EEV technology offers a distinct safety and efficacy profile compared to linear peptide approaches used by competitors like PepGen and Sarepta.
Non-clinical and early clinical data suggest superior dystrophin production and safety, with dose flexibility up to 18 mg/kg.
Lower cost of goods and efficient endosomal escape enable rapid pipeline expansion and lower manufacturing costs.
Dystrophin production in exon 45 expected to surpass current standard of care (0.8%-1.2%), with potential to capture significant market share.
Functional endpoints are evolving, with input from regulators and patient groups guiding composite measures for future studies.
U.S. adult study dose strategy post-Q2 data
EEV platform's competitive edge vs. peers
Functional benefit timeline for 44 vs 45 exons
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Entrada Therapeutics earnings date
TD Cowen 46th Annual Health Care Conference3 Mar, 2026
Entrada Therapeutics
Next Entrada Therapeutics earnings date
TD Cowen 46th Annual Health Care Conference3 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular sites traditionally considered unreachable by conventional therapies. The company's proprietary Endosomal Escape Vehicle technology facilitates the efficient intracellular delivery of diverse therapeutic modalities, including RNA, antibodies, and enzymes. This approach is being applied to develop treatments for a range of diseases, particularly in neuromuscular, ocular, metabolic, and immunological areas. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage